The dispositions of vancomycin (VCM) and gentamicin (GM) in plasma and perilymph after single and multiple administrations and the effects of multiple administrations of VCM or GM alone and the combination of both drugs on auditory function were studied in male guinea pigs. The pharmacokinetic parameters of VCM and GM obtained from plasma drug concentration-time data after single and multiple (22 days) intramuscular administrations of VCM (200 mg/kg of body weight) alone and GM (50 mg/kg) alone were not significantly different from those after combined administration of VCM (200 mg/kg) and GM (50 mg/kg). There was no change in the penetration ratio of VCM and GM into perilymph between administration of VCM or GM alone and the combination of both drugs. Furthermore, the hearing threshold of guinea pigs was not affected by VCM or GM alone or the combination of both drugs within the range of therapeutic VCM and GM levels in plasma in humans.
Vancomycin (VCM) has been widely used for the treatment of infections caused by methicillin-resistant Staphylococcus aureus (9, 11, 12, 14, 17) . Many investigators have reported VCMinduced nephrotoxicity (4-7, 10, 11, 13) and ototoxicity (1, 6, 7, 10, 18) . The incidence of ototoxicity in patients given only VCM was very low, while VCM given concomitantly with an aminoglycoside (gentamicin [GM] ) may increase the frequency of ototoxicity on retrospective clinical analysis and in animal experiments with guinea pigs (2, 3, 8) . This augmented ototoxicity may be due to changes in the disposition of VCM and GM or changes in auditory function after concurrent administration of VCM and aminoglycoside.
In the present study, we measured the VCM and GM concentrations in plasma and perilymph after intramuscular administration of VCM and GM alone or the combination of both drugs in an attempted to investigate the effect of the combination of both drugs compared with that of VCM and GM alone on auditory function in guinea pigs.
MATERIALS AND METHODS
Drugs and preparation of injectate. VCM hydrochloride and GM sulfate were donated by Shionogi Co. Ltd. (Osaka, Japan) and Schering Plough Co. (Osaka, Japan), respectively. As the injectate of VCM hydrochloride, a saline solution of 100 mg/ml for administration of VCM alone was prepared. As the injectate of GM sulfate, saline solutions of 50 and 25 mg/ml for the administration of GM alone were prepared. A mixture of saline solutions of VCM hydrochloride (100 mg/ml) and GM sulfate (25 mg/ml) for coadministration of VCM and GM was also prepared.
Pharmacokinetic study of VCM and GM in guinea pigs. Twenty male Hartley guinea pigs (270 to 340 g each) were used for the single-dose study. The animals were anesthetized with an intraperitoneal injection of sodium pentobarbital (40 mg/kg of body weight), and then a polyethylene cannula was inserted into the carotid artery of each animal for blood collection. In four animals (control), saline was administered into the left or right femoral muscle. Blood samples (0.3 ml) were collected from the cannula immediately after administration of saline, and blood urea nitrogen (BUN) levels were determined. Sixteen animals were divided into four different dose groups (VCM hydrochloride, 200 mg/kg alone; GM sulfate, 50 or 100 mg/kg alone; and the combination of VCM hydrochloride and GM sulfate [200 and 50 mg/kg, respectively]). Each drug solution was administered into the left or right femoral muscle. Blood samples (0.1 to 0.3 ml) were collected from the cannulas immediately before and at 10, 20, and 30 min and 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20 , and 24 h after the administration of VCM alone or the combination of VCM and GM, and both plasma drug concentrations were determined. For GM, blood samples were collected immediately before and at 10, 20, and 30 min and 1, 1.5, 2, 4, 6, and 8 h after the administration of GM, and the plasma GM concentrations were measured. In the remaining group (n ϭ 4), a mixture of GM and VCM was administered into the left or right femoral muscle. Blood samples were collected after 8 h for the determination of the GM concentration in plasma. All animals were immediately exsanguinated after the last collection of blood, and perilymph samples (10 to 15 l) from the bilateral inner ears were also collected via the round window and oval window of the cochleas with a glass microtube (16) , and GM and VCM levels were determined. BUN levels were determined in plasma collected immediately after administration of the drug.
Sixteen guinea pigs (270 to 430 g each) were divided into four different dose groups for the multiple-dose study (VCM hydrochloride, 200 mg/kg alone; GM sulfate, 50 or 100 mg/kg alone; and the combination of VCM hydrochloride [200 mg/kg] and GM sulfate [50 mg/kg]). Each drug was administered once a day for 22 days to the left and right femoral muscle alternately. On day 22, the animal was anesthetized with sodium pentobarbital, and a polyethylene cannula was inserted into the carotid artery before administration of VCM and/or GM. Blood samples were collected from the cannula immediately before and at 10, 20, and 30 min 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20 , and 24 h after the last administration of VCM alone or the combination of VCM and GM, and the concentrations of both drugs in plasma were determined. For GM, blood samples (0.1 to 0.2 ml) were collected immediately before and at 10, 20, and 30 min and 1, 1.5, 2, 4, 6, and 8 h after the last drug administration, and the GM concentration in plasma was determined. In the remaining group, GM plus VCM was administered once a day for 22 days. On day 22, blood samples were collected after 8 h as described for the determination of GM levels in plasma. Then, all animals were immediately exsanguinated after the last blood collection, and perilymph samples (10 to 15 l) were also collected from the bilateral inner ears via the round window and oval window of the cochleas with a glass microtube (16) , and the GM and VCM levels were determined. The BUN concentration was determined in plasma collected immediately after administration of the drug.
Determination of VCM, GM, and BUN levels in plasma and perilymph. VCM and GM levels in plasma and perilymph were determined by fluorescence polarization immunoassay (TDX; Abott). Ten to fifteen microliters of perilymph was diluted sixfold with blank plasma from healthy humans for the determination. To examine the reproducibility of the assay, a series of plasma samples containing VCM and GM were prepared (expressed as the ratio of VCM to GM [in micrograms per milliliter] 5/0, 5/2, 0/2, 20/0, 20/8, and 0/8), and five samples of each were assayed. The concentrations found (means Ϯ standard deviations) were 5.1 Ϯ 0.18 g/ml, 20.3 Ϯ 0.25 g/ml for VCM in the absence of GM, 2.1 Ϯ 0.10 g/ml, 8.1 Ϯ 0.20 g/ml for GM in the absence of VCM, 5.2 Ϯ 0.16 g/ml, 20.3 Ϯ 0.32 g/ml for VCM in the presence of GM, 2.1 Ϯ 0.08 g/ml, and 8.1 Ϯ 0.24 g/ml for GM in the presence of VCM. There were no cross-reactivities found in the determination of both drug concentrations. The detection limits for VCM and GM were 2 and 0.2 g/ml, respectively. Whenever the concentrations of VCM and GM in plasma and perilymph were determined, the control plasma known concentrations (7, 35 , and 75 g/ml for VCM; 1, 4, and 8 g/ml for GM) were assayed to check the reproducibility of the assay. The BUN concentration was determined by fluorescence polarization immunoassay (TDX; Abott).
Pharmacokinetic analysis. One compartment open model including the absorption process was used for the analysis of the concentrations in plasma after the administration of VCM and GM. The following equation was fitted to the drug concentration in plasma (C p ) by a simplex algorithm of weighted nonlinear least squares (21) with the reciprocal of concentration as a weighting factor:
where A is the concentration at time 0 on the back-extrapolated monoexponential line, k el is the elimination rate constant, k a is the absorption rate constant, and t is time. The terminal half-life (t 1/2 ) was calculated by dividing 0.693 by k el . The area under the drug concentration-time curves (AUC) in plasma after administration of the drug up to the last sampling point was calculated by the trapezoidal rule, and the AUC beyond the last observed plasma concentration (C ob ) was extrapolated according to C ob /k el .
Determination of hearing threshold. . Each solution was administered once a day for 21 days into the left or right femoral muscle alternately. The auditory threshold was determined at 24 h after the last administration by the auditory brain stem response (ABR) as previously reported (15) .
Each guinea pig was anesthetized with an intraperitoneal injection of sodium pentobarbital (40 mg/kg). To avoid binaural readings, the right inner ear was destroyed before the recordings were measured. During the experiments, the animal's body temperature was maintained with a heating pad. The experiments were performed in accordance with the principles of the Declaration of Helsinki.
Needle electrodes were inserted into the vertex and the left mastoid, and the cervical skin served as the ground.
As acoustic stimuli, short tone bursts of 1,000, 2,000, 4,000, 8,000, 16,000, and 32,000 Hz were used. Acoustic stimuli were generated and attenuated by an auditory stimulator (model 3G29; SANEI Co.) and wide-function synthesizer (model 1930; NF Co.) and were delivered in an open field via a speaker placed 90 cm away from the left ear of the guinea pig. Stimulus levels were changed in 10-dB increments. The threshold was defined as the lowest level at which wave P3 or P4 of the ABR could just be detected. The rate of stimulation was 9.5 Hz.
Auditory evoked potentials were amplified, filtered, and averaged with a Synax ER 1100 instrument (NEC-SANEI Co.). The obtained data were stored on a floppy disc and used for further analysis. After amplification and filtering (50 to 3,000 Hz), 200 responses were averaged. The analysis time was 20 ms; all responses were doubly traced to confirm the reproducibility of the responses.
Statistical analysis. Statistical analysis was performed with the Student t test, with P of 0.05 as the minimal level of significance. All results are expressed as means Ϯ standard deviations.
RESULTS
Time courses of plasma VCM concentration. Time courses of VCM concentrations in plasma after single and multiple administrations of VCM (200 mg/kg) alone and the combination of VCM (200 mg/kg) and GM (50 mg/kg) are shown in Fig. 1 . The pharmacokinetic parameters of VCM and BUN in each group are given in Table 1 . There were no significant differences in the peak drug concentration in plasma (C max ), T max (time at which the maximum VCM concentration in plasma was reached), ka, kel and AUC of VCM in plasma between the combination drug treatment group and the VCMtreated group. There were no significant differences in the time courses of plasma VCM concentrations and pharmacokinetic parameters between the multiple-and single-dose groups. No significant difference in BUN values between the control group (23.3 Ϯ 1.6 mg/dl) and GM-and/or VCM-treated groups was observed (Table 1) .
Time courses of plasma GM concentration. The GM concentration profiles in plasma after single and multiple administrations of GM (50 mg/kg) alone and the combination of GM (50 mg/kg) and VCM (200 mg/kg) are shown in Fig. 2 . With the single dose, the plasma GM concentration reached maximum levels (63.9 g/ml) at 0.5 h after administration of GM alone and (27.4 g/ml) at 0.9 h after concurrent administration with VCM. The plasma GM concentration up to 1.5 h after administration of GM alone was significantly higher than that after concurrent administration of both drugs. The T max for GM after concurrent administration was significantly greater than that after administration of GM alone, while t 1/2 was prolonged ( Fig. 2 and Table 2 ). However, there was no significant difference in the AUC 0-8 h for GM between the two treatment groups (Table 2) . Similarly, with multiple dosing, the plasma GM concentration reached maximum levels (60.7 g/ml) at 0.3 h after administration of GM alone and (31.4 g/ml) at 1.3 h after concurrent administration with VCM. The plasma GM concentration up to 1 h after administration of GM alone was significantly higher than that after concurrent administration with VCM. The T max for GM after concurrent administration with VCM was significantly greater and t 1/2 was prolonged compared with that after administration of GM alone ( Fig. 2 and Table 2 ), although there was no significant difference in the AUC 0-8 h for GM between the two treatment groups (Table 2). The time courses of plasma GM concentrations after administration of GM (50 and 100 mg/kg) alone are shown in Fig. 3 . The C max for GM after administration of a 100-mg/kg dose was twofold higher than that of 50 mg/kg in both groups of administered GM alone in single and multiple doses. a GM sulfate was administered in single or multiple doses either alone at doses of 50 and 100 mg/kg or in combination with VCM hydrochloride (GM ϩ VCM) at 50 and 200 mg/kg, respectively, to guinea pigs (n ϭ 4 in each group). The results are means Ϯ standard deviations. Results significantly different from those for GM at 50 mg/kg alone are indicated by asterisks: ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01. The Akaike Information Criteria are GM (50 mg/kg alone, single dose), Ϫ18.3 to Ϫ9.2; GM (100 mg/kg alone, single dose), Ϫ8.5 to 9.1; combination, single dose, Ϫ20.3 to Ϫ3.8; GM (50 mg/kg alone, multiple doses), Ϫ11.4 to Ϫ3.2; GM (100 mg/kg alone, multiple doses), Ϫ1.5 to 7.5; and combination, multiple doses, Ϫ10.8 to Ϫ5.8.
b t 1/2 , elimination half life. c Wt, body weight of guinea pigs.
group (23.3 Ϯ 1.6 mg/dl) and the GM-and/or VCM-treated group was observed ( Table 2) . GM and VCM concentrations in perilymph. Plasma and perilymph GM concentrations 8 h after single and multiple intramuscular administrations of the drugs in guinea pigs are listed in Table 3 . Both plasma and perilymph GM concentrations increased in the presence of VCM in the single-administration group. Plasma and perilymph GM concentrations increased with increases in the dose in both single-and multiple-administration groups. However, there were no significant differences in the perilymph-to-plasma GM concentration ratios (perilymph/plasma ratio) which ranged from 1.1 to 2.4, among all treatment groups.
Plasma and perilymph VCM concentrations at 24 h after single and multiple intramuscular administrations in guinea pigs are given in Table 4 . Plasma and perilymph VCM concentrations after both administration of VCM alone and with GM in the multiple-administration groups were higher than those in the single-administration groups. However, there was no significant difference in the perilymph/plasma ratios of VCM, which ranged from 0.5 to 0.7, among the different groups.
Hearing threshold. Hearing thresholds determined by ABR after multiple intramuscular administrations of GM alone, VCM alone, and the combination of both drugs in guinea pigs are shown in Fig. 4 . No significant differences in the profiles of the hearing threshold at any frequencies among the control group and the other groups were observed.
DISCUSSION
In the present study, there was no change in BUN values among the single-dose and multiple-dose groups given VCM alone, GM alone, and the combination of VCM and GM (Tables 1 and 2 ). This finding suggests that renal toxicity was not induced after GM and/or VCM administration in guinea pigs. It has been reported that deterioration of renal function was augumented by the concurrent administration of VCM (150 mg/kg) and tobramycin (60 mg/kg) for 4 days compared with the administration of VCM alone or tobramycin alone in rats (19) . Similar results were obtained with concurrent admin- (19) , the BUN concentrations did not increase in our study (Table 1 ). This discrepancy in the effect of VCM and aminoglycoside on renal function may be due to interspecies differences; however, the mechanism which causes this discrepancy is not known at the present time.
We also found that GM had no effect on the pharmacokinetics of VCM with both single and multiple administrations of drugs ( Fig. 1 and Table 1 ). Furthermore, aberrant accumulation of VCM in the body was not observed after multiple doses of VCM for 22 days.
Brummett et al. reported that the plasma GM concentration (45.6 g/ml) at 2 h after multiple subcutaneous administrations of GM sulfate (50 mg/kg) once a day for 16 days was higher than that (19.1 g/ml) at 2 h after single administration of GM (3). In our study, there were no differences in the plasma GM concentrations at 2 h after administration and the pharmacokinetic parameters of GM between the single-and multipledose groups, as shown in Fig. 2 and Table 2 . Furthermore, Brummett et al. reported that the plasma GM concentration in the multiple-dose group (63 g/ml) at 2 h after concurrent administration of GM (50 mg/kg) and VCM (100 mg/kg) was higher than that in the single-dose group (23.3 g/ml) (15). In our study, however, there were no differences in the plasma GM concentration and pharmacokinetic parameters between single-and multiple-dose groups ( Fig. 2 and Table 2 ). These discrepancies may be due to differences in experimental methods. Brummett et al. adopted the subcutaneous route for injection of drugs and used a radioimmunoassay method for the determination of GM and VCM concentrations in plasma and perilymph, while we determined drug concentrations by the fluorescence polarization immunoassay method after intramuscular administration of the drugs. However, the reason for the difference remains unclear.
T max of GM was prolonged and C max decreased in the VCMplus-GM-treated group compared with the GM-treated group. Since VCM and GM were simultaneously injected in the same site, the effect of interaction of both drugs on the absorption process from the muscle site to systemic circulation might be considered. A change in the pH of the injectate is one possible mechanism. The pHs of the GM solution and the mixture of GM and VCM were 4.5 and 3.6, respectively. However, when the GM solution adjusted to pH 3.5 was intramuscularly administered in guinea pigs and the GM concentration in plasma was determined, the results were similar to the data for administration of GM alone in a solution at pH 4.5 (unpublished data). From these findings, VCM may inhibit the intrinsic absorption process of GM from the muscle to systemic circulation. Further studies are needed to elucidate this phenomenon.
It was found that GM did not affect the distribution of VCM to the perilymph. Furthermore, VCM did not affect the distribution of GM to the perilymph.
In the study of ototoxicity, no significant differences among the different groups were observed (Fig. 4) . The lack of hearing impairment in the combined VCM-plus-GM treatment group differed from the report of Brummett et al. (3) . This discrepancy may be due to the difference in route of administration of VCM and GM. It may be necessary to carry out experiments similar to those of Brummett et al. (3) using high doses of VCM and GM.
In our study, the C max values of VCM and GM after the multiple administration of VCM (200 mg/kg) and GM (50 mg/kg) were 48 to 62 and 53 to 66 g/ml, respectively. These values are within the therapeutic range of VCM and a little higher than the therapeutic range of GM in humans. This finding indicates that the combination of VCM and GM has no effect on the auditory function when the levels of the drugs in plasma are maintained within their respective therapeutic ranges for humans. Furthermore, it was shown that penetration to the perilymph of each drug did not change after single and multiple administration of GM alone, VCM alone, or the combination of VCM and GM.
